PharmGen Science Inc (004720) - Net Assets
Based on the latest financial reports, PharmGen Science Inc (004720) has net assets worth ₩247.76 Billion KRW (≈ $167.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩331.46 Billion ≈ $224.63 Million USD) and total liabilities (₩83.70 Billion ≈ $56.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of PharmGen Science Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩247.76 Billion |
| % of Total Assets | 74.75% |
| Annual Growth Rate | 11.87% |
| 5-Year Change | 198.47% |
| 10-Year Change | 770.35% |
| Growth Volatility | 27.95 |
PharmGen Science Inc - Net Assets Trend (2004–2024)
This chart illustrates how PharmGen Science Inc's net assets have evolved over time, based on quarterly financial data. Also explore 004720 asset base for the complete picture of this company's asset base.
Annual Net Assets for PharmGen Science Inc (2004–2024)
The table below shows the annual net assets of PharmGen Science Inc from 2004 to 2024. For live valuation and market cap data, see 004720 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩249.43 Billion ≈ $169.03 Million |
+9.30% |
| 2023-12-31 | ₩228.21 Billion ≈ $154.66 Million |
+10.19% |
| 2022-12-31 | ₩207.12 Billion ≈ $140.36 Million |
+63.17% |
| 2021-12-31 | ₩126.93 Billion ≈ $86.02 Million |
+51.89% |
| 2020-12-31 | ₩83.57 Billion ≈ $56.63 Million |
+48.58% |
| 2019-12-31 | ₩56.25 Billion ≈ $38.12 Million |
-1.06% |
| 2018-12-31 | ₩56.85 Billion ≈ $38.52 Million |
+11.35% |
| 2017-12-31 | ₩51.05 Billion ≈ $34.60 Million |
+40.23% |
| 2016-12-31 | ₩36.41 Billion ≈ $24.67 Million |
+27.04% |
| 2015-12-31 | ₩28.66 Billion ≈ $19.42 Million |
+42.46% |
| 2014-12-31 | ₩20.12 Billion ≈ $13.63 Million |
-15.60% |
| 2013-12-31 | ₩23.83 Billion ≈ $16.15 Million |
-7.99% |
| 2012-12-31 | ₩25.90 Billion ≈ $17.55 Million |
+38.59% |
| 2011-12-31 | ₩18.69 Billion ≈ $12.67 Million |
-43.48% |
| 2005-12-31 | ₩33.07 Billion ≈ $22.41 Million |
+32.76% |
| 2004-12-31 | ₩24.91 Billion ≈ $16.88 Million |
-3.19% |
| 2004-09-30 | ₩25.73 Billion ≈ $17.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PharmGen Science Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13569869857000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩135.70 Billion | 54.40% |
| Other Components | ₩113.74 Billion | 45.60% |
| Total Equity | ₩249.44 Billion | 100.00% |
PharmGen Science Inc Competitors by Market Cap
The table below lists competitors of PharmGen Science Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lument Finance Trust Inc
NYSE:LFT
|
$62.31 Million |
|
Hydrogene De France SA
PA:HDF
|
$62.33 Million |
|
Global Fashion Group S.A
F:GFG
|
$62.34 Million |
|
THINKWARE Corporation
KQ:084730
|
$62.37 Million |
|
5E Advanced Materials Inc
NASDAQ:FEAM
|
$62.27 Million |
|
Kerjaya Prospek Property Bhd
KLSE:7077
|
$62.25 Million |
|
Heidmar Maritime Holdings Corp. Common Stock
NYSE:HMR
|
$62.24 Million |
|
RTG Mining Inc
TO:RTG
|
$62.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmGen Science Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 228,221,417,860 to 249,439,297,180, a change of 21,217,879,320 (9.3%).
- Net income of 2,790,818,530 contributed positively to equity growth.
- Other factors increased equity by 18,427,060,790.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.79 Billion | +1.12% |
| Other Changes | ₩18.43 Billion | +7.39% |
| Total Change | ₩- | 9.30% |
Book Value vs Market Value Analysis
This analysis compares PharmGen Science Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.93x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4532.82 | ₩4195.00 | x |
| 2018-12-31 | ₩4922.05 | ₩4195.00 | x |
| 2019-12-31 | ₩4818.24 | ₩4195.00 | x |
| 2020-12-31 | ₩5693.27 | ₩4195.00 | x |
| 2021-12-31 | ₩8652.42 | ₩4195.00 | x |
| 2022-12-31 | ₩13118.31 | ₩4195.00 | x |
| 2023-12-31 | ₩12706.81 | ₩4195.00 | x |
| 2024-12-31 | ₩13736.10 | ₩4195.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmGen Science Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.63%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.46x
- Recent ROE (1.12%) is below the historical average (5.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 7.14% | 4.66% | 0.76x | 2.01x | ₩-947.11 Million |
| 2013 | -15.50% | -9.49% | 0.99x | 1.65x | ₩-6.09 Billion |
| 2014 | -22.71% | -10.37% | 1.05x | 2.08x | ₩-6.60 Billion |
| 2015 | 7.20% | 3.42% | 1.30x | 1.62x | ₩-804.10 Million |
| 2016 | 9.47% | 4.83% | 1.11x | 1.76x | ₩-192.33 Million |
| 2017 | 8.47% | 5.41% | 1.17x | 1.34x | ₩-777.89 Million |
| 2018 | 7.87% | 5.01% | 0.91x | 1.73x | ₩-1.21 Billion |
| 2019 | 0.54% | 0.32% | 0.95x | 1.78x | ₩-5.31 Billion |
| 2020 | 11.04% | 9.55% | 0.71x | 1.62x | ₩869.58 Million |
| 2021 | 25.58% | 29.55% | 0.50x | 1.74x | ₩19.77 Billion |
| 2022 | 33.82% | 46.42% | 0.48x | 1.53x | ₩49.35 Billion |
| 2023 | 2.67% | 3.65% | 0.50x | 1.47x | ₩-16.73 Billion |
| 2024 | 1.12% | 1.63% | 0.47x | 1.46x | ₩-22.15 Billion |
Industry Comparison
This section compares PharmGen Science Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $65,191,849,335
- Average return on equity (ROE) among peers: -1.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmGen Science Inc (004720) | ₩247.76 Billion | 7.14% | 0.34x | $62.30 Million |
| Korean Drug Co. Ltd (014570) | $65.05 Billion | 5.99% | 0.17x | $30.72 Million |
| Chorokbaem Healthcare Co Ltd (118000) | $18.71 Billion | -15.55% | 0.96x | $242.13 Million |
| BCWORLD PHARM. Co. Ltd (200780) | $79.55 Billion | 0.35% | 1.30x | $30.80 Million |
| Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) | $97.46 Billion | 4.95% | 1.31x | $132.95 Million |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more